131184-73-1|(2-Aminothiazol-5-yl)methanol| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 131184-73-1 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 131184-73-1 ]

CAS No. :	131184-73-1
Formula :	C₄H₆N₂OS
M.W :	130.17
SMILES Code :	OCC1=CN=C(N)S1
MDL No. :	MFCD06203018
InChI Key :	TZEMBFLDHOUKNI-UHFFFAOYSA-N
Pubchem ID :	11217273

Safety of [ 131184-73-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 131184-73-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	8
Num. arom. heavy atoms	5
Fraction Csp3	0.25
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	2.0
Molar Refractivity	32.65
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	87.38 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.93
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	-0.24
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.07
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-1.08
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.29
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.19

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-0.89
Solubility	16.7 mg/ml ; 0.128 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.14
Solubility	9.49 mg/ml ; 0.0729 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.73
Solubility	24.4 mg/ml ; 0.187 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-7.26 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.22

Application In Synthesis of [ 131184-73-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 131184-73-1 ]
Downstream synthetic route of [ 131184-73-1 ]

[ 131184-73-1 ] Synthesis Path-Upstream 1~3

1
[ 1003-61-8 ]
[ 131184-73-1 ]

Yield	Reaction Conditions	Operation in experiment
43%	With sodium tetrahydroborate In methanol for 1 h; Cooling with ice	2-Amino-5-formylthiazole (11.5 g, 90 mmol) was dissolved in methanol (120 mL), and sodium borohydride (5.11 g, 135 mmol) was added thereto while cooling with ice, followed by stirring at the same temperature for 1 hour. Acetone (6 mL) and water (10 mL) were added to the reaction mixture, followed by stirring. The residue obtained by evaporating the reaction mixture under reduced pressure was purified using medium pressure silica gel flash column chromatography (methanol:chloroform=1:15), thereby giving the title compound (5.09 g, 43percent) as a white solid.

References: [1] Farmaco, 1989, vol. 44, # 11, p. 1011 - 1030.
[2] Patent: US2013/165438, 2013, A1, . Location in patent: Paragraph 0349.

2
[ 32955-21-8 ]
[ 131184-73-1 ]

Yield	Reaction Conditions	Operation in experiment
225 mg	With lithium aluminium tetrahydride In tetrahydrofuran at 20℃; for 2.25 h; Inert atmosphere; Reflux	[00363] A suspension of ethyl 2-amino-1,3-thiazole-5-carboxylate (1.72 g, 10 mmol) in anhydrous THF (100 mL) was cooled in an ice bath and treated with LiAIH4 (0.76 g, 20 mmol) portionwise, under nitrogen. The reaction mixture was warmed to room temperature and stirred for 90 minutes. After this time, additional LiAIH4 (0.76 g, 20 mmol) was added and thesuspension was heated to reflux for 45 minutes. After this time, the suspension was cooled in an ice bath and cautiously treated with ice chips, followed by concentrated aqueous ammonium hydroxide solution (10 mL) and stirred for 60 hours. The orange suspension was filtered through CeliteTM, washing with MeOH. The filtrate was evaporated under reduced pressure, adsorbed onto silica and purified by flash column chromatography, eluting with MeOH/DCM (5-10percent), with the desired fractions combined and concentrated under reduced pressure to afford the title compound (225 mg). LCMS method: Method 5, RT: 0.55 mm, Ml: 131 [M+1]

References: [1] Patent: WO2016/124938, 2016, A1, . Location in patent: Paragraph 00363-00364.

3
[ 765-34-4 ]
[ 131184-73-1 ]

References: [1] Patent: US6265553, 2001, B1, .

[ 131184-73-1 ] Synthesis Path-Downstream 1~35

1
[ 1003-61-8 ]
[ 131184-73-1 ]

Yield	Reaction Conditions	Operation in experiment
72.7%	With methanol; sodium tetrahydroborate; at 0℃; for 3h;	At 0 C,Compound2-amino-5-Aldehydethiazole (12.0 g, 90 mmol) was dissolved in anhydrous methanol (250 mL), and sodium borohydride (10.0 g, 90 mmol) was slowly added and stirred for 3.0 h.The reaction was quenched by the addition of distilled water (20 mL).Dichloromethane extraction (50 mL × 3), anhydrous sodium sulfate (10 g), dried.Concentration gave 8.8 g of a yellow-brown solid.Yield: 72.7%.
43%	With sodium tetrahydroborate; In methanol; for 1h;Cooling with ice;	2-Amino-5-formylthiazole (11.5 g, 90 mmol) was dissolved in methanol (120 mL), and sodium borohydride (5.11 g, 135 mmol) was added thereto while cooling with ice, followed by stirring at the same temperature for 1 hour. Acetone (6 mL) and water (10 mL) were added to the reaction mixture, followed by stirring. The residue obtained by evaporating the reaction mixture under reduced pressure was purified using medium pressure silica gel flash column chromatography (methanol:chloroform=1:15), thereby giving the title compound (5.09 g, 43%) as a white solid.

References: [1]Patent: CN104744446,2019,B .Location in patent: Paragraph 1250; 1262-1264.
[2]Il Farmaco,1989,vol. 44,p. 1011 - 1030.
[3]Patent: US2013/165438,2013,A1 .Location in patent: Paragraph 0349.

2
[ 1001-58-7 ]
[ 131184-73-1 ]
[ 131184-75-3 ]

References: [1]Il Farmaco,1989,vol. 44,p. 1011 - 1030.

3
[ 156-57-0 ]
[ 131184-73-1 ]
2-<(2-amino-5-thiazolyl)methylthio>ethylamine dibromide [ No CAS ]

References: [1]Il Farmaco,1989,vol. 44,p. 1011 - 1030.

4
[ 765-34-4 ]
[ 131184-73-1 ]

Yield	Reaction Conditions	Operation in experiment
	With thiourea;	EXAMPLE 2 Preparation of 2-amino-5-hydroxymethylthiazole: The epoxy propanal solution from example 1 is cooled to 0 C. With vigorous stirring, 76 g (1.00 mole) of thiourea was added in portions. After the addition is complete the water is removed under vacuum on a rotatory evaporator. A red-brown oil is isolated as the product (91.3 g).

References: [1]Patent: US6265553,2001,B1 .

5
[ 1151240-86-6 ]
[ 131184-73-1 ]
[ 1151240-67-3 ]

Yield	Reaction Conditions	Operation in experiment
1.25%	With potassium carbonate; In acetonitrile; at 40℃; for 48h;	Example 46: {2-[({1-[(3,4-Dichlorophenyl)methyl]-1 H-1 ,2,3-triazol-4-yl}methyl)amino]- 1 ,3-thiazol-5-yl}methanolTo a solution of 4-(bromomethyl)-1-[(3,4-dichlorophenyl)methyl]-1 H-1 ,2,3-triazole (Intermediate 17) (0.21 g, 0.65 mmol) in acetonitrile was added (2-amino-1 ,3-thiazol-5- yl)methanol (0.175 g, 2 eq) followed by potassium carbonate (0.185 g, 2 eq) The reaction was stirred at 400C for 2 days. After evaporation, the residue was dissolved in ether and ethyl acetate and washed with water. The organic phase was dried over sodium sulphate, filtered and evaporated. The compound was purified by flash chromatography eluting with DCM/MeOH (92/8). The title compound was obtained as an <n="56"/>ochre powder (3 mg, 1.25%). HRMS calculated for Ci4H13CI2N5OS (M+H)+ 370.0296, found: 370.0297, Rt: 2.35 min. LC/MS: m/z 370 (M+H)+ Rt: 2.60 min.

References: [1]Patent: WO2009/60054,2009,A1 .Location in patent: Page/Page column 54-55.

6
[ 288-13-1 ]
[ 131184-73-1 ]
[ 1194551-59-1 ]